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1. Introduction
In spite of a decline in incidence and mortality of gastric cancer over the last decades, it is
still the fourth most common cancer and the second most common cause of cancer death in
the world. The differences in prevalence of gastric cancer have been explained as a multifac‐
torial process with an interaction involving both infection with Helicobacter pylori as a trig‐
gering factor and host genetic susceptibility as an important explanation for interindividual
variation in gastric cancer risk. To discuss the genetic host polymorphisms, we classified
them into first stage and second stage host genetic factors. In the first stage, H. pylori related
inflammation seems to play a critical role in the development of gastric cancer; in the second
stage, participation of tumor suppressor proteins and oncogenes appears to define the
course of the disease. At present, there is no definitive host genetic risk marker, and evi‐
dence suggests that each proposed host risk factor should be evaluated in specific ethnic
populations to define its importance. In this chapter, we present the most relevant up to date
data on genetic polymorphisms that have been associated with an increased risk for the de‐
velopment of gastric cancer, its potential role in the development of this neoplasia, and its
interplay with the virulence factors of the bacteria.
2. Epidemiology of gastric cancer
Stomach cancer is the fourth most common cancer worldwide with 930, 000 cases diagnosed
in 2002 [1]. Despite a major decline in incidence and mortality over the last decades, stom‐
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ach cancer is still the fourth most common cancer and the second most common cause of
cancer death in the world, accounting for more than 803, 000 deaths each year.
It has been observed that there is a 10-fold variation in incidence between populations with
the highest and lowest risk. For instance, the incidence of gastric adenocarcinoma is higher
in East Asia, Central America, and South America than in most other parts of the world and
is about twice as high among men [2]. This neoplasia is rare before the age of 40, and its inci‐
dence peaks in the seventh decade of life [3]. According to the National Cancer Institute,
gastric cancer is more common in people over the age of 72 (National Cancer Institute) and
the diagnosis of gastric cancers is frequently made based on dyspeptic and alarm symptoms.
Unfortunately, sometimes alarm symptoms are not sufficiently sensitive to detect malignan‐
cies. Dysphagia, weight loss and a palpable abdominal mass appear to be major independ‐
ent prognostic factors in gastric cancer, but when these symptoms appear, the patients are
usually in advanced stages of cancer [4].
The difference in the prevalence of gastric cancer throughout the world has been described
from different points of view. One of the most accepted explanations is that the develop‐
ment of gastric cancer is multifactorial with an interplay involving both infection with Heli‐
cobacter pylori and host polymorphisms in a process initiated by specific H. pylori genotypes
and the host immune response [5].
3. Gastric cancer and Helicobacter pylori
H. pylori is a Gram-negative spiral-shaped bacterium that persistently colonizes the human
stomach. It is the most common chronic bacterial infection worldwide and is associated with
diverse clinical outcomes that range from asymptomatic gastritis to more serious conditions,
such as peptic ulcer disease and gastric cancer [6, 7].
In general, countries with a high incidence of stomach cancer have a high prevalence of H.
pylori infection but in Europe only a small fraction of those infected by H. pylori develop
stomach cancer [8]. In Japan, the country with the highest incidence of stomach cancer in the
world, it has been estimated that of the 60 million people infected by H. pylori, only 0.4%
had stomach cancer [9].
The worldwide prevalence of H. pylori is more than 50% in the adult population and the in‐
cidence of H. pylori related diseases varies considerably throughout the world. After the dis‐
covery of H. pylori, it was reported that H pylori-positive subjects have a two to three-fold
increased risk of developing gastric cancer when compared with H pylori-negative subjects.
The risk was even higher in subjects infected with strains encoding the H pylori cagA, vacA
s1 and babA2, which are the main virulence genes related to this bacterium [10, 11].
One of the most prominent differences in gene content among H. pylori strains is the pres‐
ence or absence of a 40-kb region of chromosomal DNA known as the cag pathogenicity is‐
land (PAI) [12, 13]. This island involves the cagA-encoded CagA protein, which is delivered
into gastric epithelial cells via the bacterial type IV secretion system, where it undergoes ty‐
Gastric Carcinoma- New Insights into Current Management76
rosine phosphorylation by Src and Abl kinases. Tyrosine-phosphorylated CagA then ac‐
quires the ability to interact with and deregulate SHP-2 phosphatase, the deregulation of
this enzyme is involved in a variety of human malignancies (Figure 1). CagA also binds to
and inhibits PAR1b/MARK2 polarity-regulating kinase to alter tight junctions and epithelial
apical-basolateral polarity. These CagA activities may collectively contribute to the transfor‐
mation of gastric epithelial cells [14].
Despite the overwhelming evidence that H. pylori infection is a risk factor for noncardia gastric
cancer, accumulating evidence shows that although H. pylori eradication is relatively simple
to accomplish. Impacting the global burden of gastric cancer will be a more difficult challenge.
H. pylori infection is a key risk factor for chronic atrophic gastritis, an established precursor
of gastric cancer. There is increasing evidence of frequent elimination of the infection during
progression of chronic atrophic gastritis and it has been proposed that there is a higher elim‐
ination of H. pylori during the development of the disease [15].
H. pylori,cagA+ strain, is an established risk factor for stomach cancer and H. pylori infection
and cagA+ status have been inversely associated with a new diagnosis of Barrett’s esopha‐
gus [16]. The findings are consistent with the hypothesis that H. pylori colonization protects
against Barrett’s esophagus and that the association may be at least partially mediated
through Gastroesophageal Reflux Disease (GERD).
It has been recently proven that H pylori infection is associated with significantly reduced
risks of esophageal adenocarcinoma and adenocarcinomas of the esophagogastric junction
but not with squamous cell carcinomas [17].
Figure 1. Cag A is translocated through a type IV secretion system. Once inside the cell, it is tyrosine-phosphorylated
and binds to and activates Src homology 2-containing protein-tyrosine phosphatase-2 (SHP-2).
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Infection with cagA-positive H. pylori seems to play an essential role in the development of
gastric carcinoma [18], although the bacteria alone cannot be considered a unique factor in
the promotion of gastric cancer. Host susceptibility has also been involved in this process,
the interaction of some H. pylori genotypes, in relation to host polymorphisms can lead to
gastric cancer. When H. pylori is eliminated in patients treated for early stage gastric cancer,
the risk of developing a second gastric cancer decreases by two-thirds [19].
4. Host genetic polymorphisms and cancer susceptibility
Host genetic factors play an important role in influencing disease risk, but identifying candi‐
date genes is a major challenge that requires a fundamental understanding of the disease
[20]. The best-established risk factors for stomach cancer are H. pylori infection--by far the
strongest established risk factor for distal stomach cancer--as well as male gender, a family
history of stomach cancer, and smoking [21, 22].
5. Gastric carcinogenesis.
The precancerous process had been the subject of inquiry way before the scientific commun‐
ity was aware of H. pylori as a human pathogen. The histopathology of the precancerous
stages has long been recognized: chronic gastritis, gland loss (atrophy), intestinal metaplasia
(complete and incomplete), and epithelial dysplasia. Progression of the process in high-risk
populations has been documented [23, 24].
Figure 2. Modified model of carcinogenesis proposed by Correa Pelayo. H. pylori acts as a pivotal factor in the devel‐
opment of gastritis. Increased chronic inflammation is influenced by genetic susceptibility factors (fist stage genes)
and progression of the disease is strongly influenced by second stage genes. Table 1 resumes both the first stage and
second stage genes
The discovery of H. pylori strongly supported the carcinogenesis model triggering the re‐
sponse (Figure 2), with other factors having important roles in the progression thorough the
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carcinogenesis cascade. In the next paragraphs, some of the host factors involved will be dis‐
cussed. The first group of genes related to host susceptibility is the “first stage genes”, i.e.,
which influence the first stage of the cascade and are related to a more intense inflammatory
response after gastritis associated to H. pylori infection is clearly established in the stomach.
“Second stage genes” seem to have an important role after atrophic gastritis has been estab‐
lished. The inflammatory process leads to in situ mutations and strong activity of antitumor
genes such as p53 and oncogenes such as c-fos, c-jun c-met, K-sam, and K-ras.
Protein/Effectors Polymorphism or
alleles
Effect References
First stage
Interleukin-1 beta and its
receptor antagonist
IL-1B-31*C
IL-1B-511*T
IL-1RN*2
High-level expression of IL-1B, reduction of acid
output
corpus and colonization by H. pylori.
IL-1B-31*C, IL-1B-511*T, and IL-1RN*2 alleles
are associated to an increased risk of gastric
cancer.
[25 - 32]
Interleukin-8 IL-8-251 High IL-8 levels are found in gastric cancer.
IL-8-251 *A allele is associated to a higher
production of IL-8.
[33 - 37]
Nucleotide-binding
oligomerization domain
containing 2 (NOD2)
NOD2 R702W NOD2 is upregulated in gastric epithelial cells
of patients with chronic infection by H. pylori.
NOD2 R702W has been associated to gastric
lymphoma.
[38, 39]
Cyclooxygenase 2 (COX-2)PTGS2 5939C COX-2 is over-expressed in gastric cancer and
in H. pylori infection.
PTGS2 5939C allele carriers were at increased
risk of gastric cancer.
[40 , 41]
Toll like receptor 4 TLR4 Asp299Gly
TLR4 Thr399Ile
TLR4+3725 G/C
TLR-4 is associated to hyporesponsiveness to
LPS and therefore to H. pylori.
[22 , 42]
Interleukin-10 IL-10 -1082 G/A
IL-10 −819 C/T
IL-10 −592 C/A
IL-10 ATA
IL-10 GCC
IL-10 ACC
Low secretion of IL-10 is associated to high
inflammation and high risk to gastric cancer.
Haplotype ATA is low IL-10 secreting and
haplotype GCC is high IL-10 secreting.
[43]
Selenoprotein S SEPS1 -105 G/A Selenoprotein S participate in retro-
translocation of misfolded proteins from the
endoplasmic reticulum to the cytosol for their
degradation.
[44 - 46]
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Protein/Effectors Polymorphism or
alleles
Effect References
Association between the proximal promoter
SEPS1 -105G/A polymorphism with circulating
levels of pro-inflammatory IL-1β and TNF-α
Selenoprotein S (SEPS1) gene -105G"/A
promoter polymorphism influences the
susceptibility to gastric cancer in the Japanese
population.
Reactive oxygen species
(ROS) and reactive
nitrogen species (RNS)
Production of ROS and RNS increase gastric
inflammation and therefore carcinogenesis.
H. pylori-induced ROS production affects
gastric epithelial cell signal transduction,
resulting in gastric carcinogenesis.
[47]
Survivin Survivin downregulation correlate with
apoptosis.
Infection with H. pylori decreases survivin levels
in the mucosa of patients with gastritis.
[48]
Second stage
E-cadherin CDH1, OMIM +192090 E-cadherin is a calcium dependent cell-cell
adhesion glycoprotein.
Heterozygous germline point or small
frameshift mutations in the E-cadherin gene
(CDH1, OMIM +192090) is associated with
diffuse cancer.
[3, 49]
p53 p53 codon 72
Two alleles encoding
either arginine (CGC)
or proline (CCC)
Repair of DNA. When p53 mutates, DNA-
damaged cells are not arrested in G1 and DNA
repair does not take place, allowing other
mutations to accumulate and conduce to
neoplasic transformation and cancer.
p53 codon 72 polymorphism has been
associated with gastric cancer.
[50 - 53]
Oncogene RAS Down regulation of Ras proteins in cancer lead
to increased invasion and decreased apoptosis.
Mutations in the RAS family are common, and
have been found in 20% to 30% of all human
tumors
[54]
Oncogene MYC Involved in cell cycle regulation, cell growth
arrest, cell adhesion, metabolism, ribosome
biogenesis, and protein synthesis
[55]
Table 1. First and second stage genes that have been associated to the development of gastric cancer
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6. First stage genes
6.1. Interleukin 1 Family
The association of IL-1 polymorphisms to gastric cancer has a deep principle: alleles IL-1B-31*C,
IL-1B-511*T, and IL-1RN*2, lead to high-level expression of IL-1β, reduction of acid output,
corpus-predominant colonization by H. pylori, pangastritis, atrophic gastritis, and increased
risk of gastric cancer. The importance of the IL-1beta gene polymorphism with an increased
risk of developing hypochlorhydria and gastric atrophy, which is considered a gastric can‐
cer precursor, was first demonstrated in a Caucasian population [25] and later reported in
other populations [26, 28-32, 56, 57]. El Omar et al. found that risk increases progressively and
that individuals with three or four polymorphisms in IL-1, IL1-RN or IL10 and infected with
H. pylori have a 27-fold increased risk of developing non-cardia cancer.
The interaction between a host’s immunological defenses, and environmental and H. pylori
virulence factors play an important role in the development of gastric cancer [58, 59]. Other
researchers confirmed that the allelic variation in IL1-beta seems insufficient for the devel‐
opment of gastric cancer. Figueiredo et al. investigated combinations of bacterial and host
genotypes in association with gastric cancer and found that a high proportion of gastric car‐
cinoma patients were carriers of IL-1 beta-511*T (69%) allele. The results on the association
between IL-1 β polymorphisms and gastric cancer risk remained inconclusive [60].
An association between these polymorphisms was not found in some populations [60, 61];
[62-67], suggesting that this divergence may reflect the different genetic background related
to ethnicity and the potential confounding variables, such as H. pylori status and family his‐
tory of malignancy.
6.2. Interleukin 8 and TNFA
Since the watershed publication of El-Omar et al. linking polymorphisms in genes regulat‐
ing the gastric inflammatory responses to gastric cancer risk due to H. pylori, many groups
have been investigating other susceptibility loci ruled by polymorphic alleles, particularly
those of the innate immune response. One of the most studied is Interleukin-8 (IL-8), which
is a potent chemokine that may play a role in gastric cancer pathogenesis.
Gastric cancer specimens have increased IL-8 protein levels, and many gastric cancer cell
lines express high levels of IL-8 mRNA and the protein [34-36]. The IL-8-251 polymorphism
might be a host susceptibility factor for gastric carcinoma development and angiogenesis in
gastric carcinogenesis [37] but this association is likely to be ethnic-specific [68] because sev‐
eral studies have reported an association with gastric cancer [33, 69, 70]. This association has
not been confirmed in studies of Caucasian populations [71, 72]. Another of the studied
genes is TNFA. In relation to this gene, the TNFA-308 allele, which is thought to increase the
production of TNF-alfa, confers an increased risk for the development of gastric cancer. This
polymorphism increases the risk for non-cardia gastric cancer by approximately two-fold.
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6.3. NOD1, NOD2, COX2, ROS and RNS
The pathogen-associated intracellular recognition molecules NOD1 and NOD2 are impor‐
tant regulators of chronic inflammation. NOD1 appears to be involved in the activation of a
key transcription factor, NF-kB, by the Cag pathogenicity island [39]. Rosenstiel et al. report‐
ed that NOD1 and NOD2 were upregulated in the gastric epithelial cells of patients with
chronic infection by H. pylori, the NOD2 variant R702W was more prevalent in patients with
gastric lymphoma than in H. pylori-infected individuals with gastritis or gastric ulcers [38].
Cyclooxygenase2 (COX-2) has long been known to be over-expressed in gastric cancer and
in H. pylori infection. Studies of gastric cancer cases and controls with preneoplastic lesions
from China, showed an association between specific COX-2 genotypes with high level
COX-2 expression and gastric cancer risk [40]. On the other hand, Reactive oxygen species
(ROS) and reactive nitrogen species (RNS) have been implicated in increasing gastric inflam‐
mation and therefore carcinogenesis. The mechanism by which the bacteria induce gastric
carcinogenesis is not defined. It has been reported that H. pylori produces ROS in addition to
ROS/RNS by activated neutrophils. Some studies have revealed that H. pylori-induced ROS
production affects gastric epithelial cell signal transduction, resulting in gastric carcinogene‐
sis. ROS/RNS production in the stomach can damage DNA in gastric epithelial cells, thus
increasing the risk of gastric carcinogenesis [47].
6.4. Survivin
The expression of the inhibitor-of-apoptosis protein survivin in adults is frequently linked to
the development of cancer. Recently, it has been found that infection with H. pylori de‐
creased survivin protein levels in the mucosa of patients with gastritis. Moreover, survivin
downregulation correlated with apoptosis and a loss of cell viability in gastrointestinal cells
infected with different H. pylori. Overexpression of survivin in gastric cells reducing cell
death after infection with H. pylori [48] has also been reported. This may have some implica‐
tions in gastric carcinogenesis.
6.5. Toll-like receptor 4
Recognition of pathogens is mediated by a set of germline-encoded receptors that are refer‐
red to as pattern-recognition receptors (PRRs). These receptors recognize conserved molecu‐
lar patterns, which are found in many species of microorganisms. An important PRR is Toll-
like receptor 4 (TLR4), a transmembrane receptor that recognizes a range of ligands,
including lipopolysaccharide (LPS), which is found in Gram-negative bacteria like H. pylori
[73]. TLR-4 polymorphisms have been associated with a variety of inflammatory conditions,
where defective signaling through TLR-4 is thought to trigger an inappropriate inflammato‐
ry response.
Two single nucleotide polymorphisms (SNPs) in the TLR4 gene, Asp299Gly and Thr399Ile
transitions,  have  been  shown  to  lead  to  hyporesponsiveness  to  LPS,  reduced  epithelial
TLR4 density and reduced inflammatory cytokine response to LPS [42]. TLR4 Asp299Gly
and Thr399Ile polymorphisms have been reported to be a risk factor for gastric carcino‐
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ma or its precursors in Caucasian and Indian populations. Also the TLR4+3725 G/C poly‐
morphism  has  been  described  as  a  risk  factor  of  severe  gastric  atrophy  in  H.  pylori
seropositive Japanese [22].
Hold et al. addressed the role of TLR with respect to H. pylori infection in gastric carcinogen‐
esis by the study of patients previously investigated for cytokine polymorphisms and sus‐
ceptibility to gastric cancer from Poland, Scotland, and the United States. An association
between a polymorphism in TLR-4 and an increased risk of noncardia gastric cancer and its
precursor lesions including achlorhydria was identified in that study [74]. This association
was specific for noncardia gastric cancer as it was not observed in esophageal or gastric car‐
dia cases and remained even after correcting for the polymorphic variations in IL-1β and the
IL-1 receptor previously documented by this group.
6.6. Interleukin 10
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that downregulates the production
of Th1-derived cytokines [75] and seems to limit and terminate the inflammatory response
by the blocking proinflammatory cytokine secretion. Some functional polymorphisms have
been described for the IL-10 gene promoter. The single-nucleotide polymorphisms (SNP) at
positions -1082 (G/A), −819 (C/T), and −592 (C/A) from the transcriptional start site are in
linkage disequilibrium, and are responsible for three different haplotypes formed by the
combination of ATA, GCC and ACC. The IL-10 haplotypes and cytokine production have
been correlated with counterpointing results [46, 76, 77].
A higher prevalence of gastric cancer in patients with the proinflammatory (low IL-10 se‐
creting) haplotype ATA has been reported, but contrasting results have also reported an as‐
sociation between carcinoma and the anti-inflammatory (high IL-10 secreting) haplotype
GCC [43]. The study of Rad et al. showed that this contrastive observation might be ex‐
plained by the finding that cagA + strains were more prevalent among GCC carriers [32].
Further studies are needed to clarify the role of IL-10 polymorphisms in H pylori infection.
6.7. Selenoprotein S
Selenoprotein S participates in the retro-translocation of misfolded proteins from the endo‐
plasmic reticulum to the cytosol for their degradation [44]. This membrane protein functions
in stress responses to prevent the deleterious consequences of accumulation of misfolded
proteins, accumulation that has been linked to immune and inflammatory processes.
A strong association between the proximal promoter SEPS1 polymorphism at -105G/A with
circulating levels of pro-inflammatory IL-1β and TNF-α has been reported [45]. A regulatory
loop has been recently proposed whereby cytokines stimulate the expression of SEPS1,
which in turn diminishes cytokine production [15]. The -105G>A promoter polymorphism
of SEPS1 has been associated with the intestinal type of gastric cancer [46]. In another report
of stomach biopsies from 268 Japanese gastric cancer and 306 control patients found that
carrying the SEPS1-105*A allele was associated with an increased risk of intestinal type gas‐
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tric cancer (OR: 2.0, 95%CI 1.0–3.9, p < 0.05) as well as of gastric cancer located in the middle
third of the stomach (OR: 2.0, 95% CI 1.0–3.9, p < 0.05).
7. Second stage genes
External environmental exposures play an important role. These can give rise to a number of
different genetic changes, the most common of which include chromosomal changes such as
loss of heterozygosity (LOH), rearrangements, deletions, gains, and translocations; gene mu‐
tations such as base substitutions, small insertions and deletions, allelic loss, amplification
and rearrangements; and epigenetic events such as alteration in DNA methylation. Loss of
tumor suppressor function leads to the initiation and progression of cancer [78, 79]. Inactiva‐
tion of tumor suppressor genes can result from both genetic mechanisms, such as mutation,
and epigenetic mechanisms, such as DNA hypermethylation.
7.1. E-cadherin
E-cadherin is a calcium dependent cell-cell adhesion glycoprotein. Mutations in this gene
are associated with gastric, breast, colorectal, thyroid and ovarian cancer [80]. It has been re‐
ported that promoter hypermethylation of E-cadherin plays an important role in gastric car‐
cinogenesis [49]. Evidence shows that a heterozygous germline point or small frameshift
mutations in the E-cadherin gene (CDH1, OMIM +192090) are associated with diffuse cancer
[81]. Carriers of CDH1 germline mutations have an accumulative GC risk, before age 75, of
40–67% for men and 63–83% for women [82].
7.2. P53
The p53 gene has been called the genome guard is critical in maintaining orderly prolifera‐
tion of cells. Normally, damage to cellular DNA initiates increased expression of p53 that
may lead to the arrest of the cell cycle. This interruption allows DNA repair to occur before
abnormal proliferation is produced. If DNA repair is not successful, then the cell undergoes
apoptosis to avoid proliferation of mutated cells. When p53 mutates, DNA-damaged cells
are not arrested in G1 and DNA repair does not take place, allowing other mutations to accu‐
mulate and conduce to neoplasic transformation and cancer. Mutation of p53 is probably the
most significant genetic change characterizing the transformation of cells from normal to
malignant [83]. With this principle, one of the most known polymorphisms in p53 have been
studied in relation to gastric cancer and some polymorphisms in this gene have been associ‐
ated with the development of distal GC in Mexican, Chinese, Korean and Japanese popula‐
tions [51, 53]. A meta-analysis suggests that the p53 codon 72 polymorphism may be
associated with gastric cancer particularly among Asians, and that the difference in geno‐
type distribution may be associated with the location, stage, and histological differentiation
of gastric cancer.
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7.3. Oncogenes
Once activated, a proto-oncogene or its product is a tumor-inducing protein [84]. Some of
the well-known oncogenes are RAS, WNT, MYC, ERK, and TRK. Among these, one of the
most studied is MYC, which is involved in multiple cellular functions, such as cell cycle
regulation, cell growth arrest, cell adhesion, metabolism, ribosome biogenesis, protein syn‐
thesis, and mitochondrial function. It has a main role in several carcinogenesis processes
in humans [55].
The RAS family is responsible for cell proliferation and functions. They act as a switch that
controls intracellular signaling networks in processes such as actin cytoskeleton integrity,
proliferation, differentiation, cell adhesion, apoptosis and cell migration. Ras proteins are of‐
ten deregulated in cancers, leading to increased invasion and decreased apoptosis. Muta‐
tions in the RAS family are common, and have been found in 20% to 30% of all human
tumors [54], but no specific mutation has been consistently related to gastric cancer.
8. Conclusions
Host genetic susceptibility has been suggested as one of the most important possible explan‐
ations for interindividual differences in gastric cancer risk and even to tumor invasion. In
the first stage, inflammation seems to play a critical role in the development of many types
of cancer, including gastric cancer and genetic changes in gene coding some crucial media‐
tors in the inflammatory response may play an essential role in Helicobacter pylori-infected
individuals. In the second stage, participation of tumor suppressor proteins and oncogenes
seems to define the course of the disease.
In conclusion, there are currently no definitive genetic risk markers for gastric cancer risk
that can be applied to all populations. We need to recognize that distal gastric cancer is a
multifactorial event. We do not discuss the effect of the environment that may influence
both bacteria and the host factors.
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